Patents by Inventor Ming-Hong Hao
Ming-Hong Hao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240368140Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: February 20, 2024Publication date: November 7, 2024Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Tuoping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
-
Patent number: 11926619Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: GrantFiled: April 8, 2019Date of Patent: March 12, 2024Assignee: Eisai R & D Management Co., Ltd.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Lisa A. Marcaurelle, Marta Nevalainen, Ming-Hong Hao, Morgan Welzel O'Shea, Parcharee Tivitmahaisoon, Sudeep Prajapati, Tuoping Luo, Nicholas C. Gearhart, Jason T. Lowe, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Andrew Cook, Shelby Ellery, Atsushi Endo, James Palacino, Dominic Reynolds
-
Patent number: 11498916Abstract: A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.Type: GrantFiled: December 20, 2019Date of Patent: November 15, 2022Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: George Moniz, Kristen Sanders, Arani Chanda, Kenshi Yoshida, Ming-Hong Hao, Dominic Reynolds, Sudeep Prajapati, Anand Selvaraj, Takashi Satoh, John Wang
-
Patent number: 11339188Abstract: Provided herein are compounds useful for the treatment of cancer.Type: GrantFiled: February 4, 2020Date of Patent: May 24, 2022Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
-
Publication number: 20210205348Abstract: Provided herein are methods for the treatment of bladder cancer.Type: ApplicationFiled: May 31, 2019Publication date: July 8, 2021Applicant: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
-
Publication number: 20210163456Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: April 8, 2019Publication date: June 3, 2021Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
-
Patent number: 10912774Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.Type: GrantFiled: December 17, 2019Date of Patent: February 9, 2021Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
-
Patent number: 10851065Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.Type: GrantFiled: September 22, 2017Date of Patent: December 1, 2020Assignee: Eisai R&D Management Co., Ltd.Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
-
Publication number: 20200299321Abstract: Provided herein are compounds useful for the treatment of cancer.Type: ApplicationFiled: February 4, 2020Publication date: September 24, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
-
Publication number: 20200255415Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.Type: ApplicationFiled: November 22, 2017Publication date: August 13, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux, Sudeep Prajapati, Dominic Reynolds, Morgan O'Shea, Thiwanka Samarakoon
-
Publication number: 20200206222Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.Type: ApplicationFiled: December 17, 2019Publication date: July 2, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Dominic REYNOLDS, Ming-Hong HAO, John WANG, Sudeep PRAJAPATI, Takashi SATOH, Anand SELVARAJ
-
Patent number: 10618930Abstract: Provided herein are compounds useful for the treatment of cancer.Type: GrantFiled: February 15, 2019Date of Patent: April 14, 2020Assignee: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
-
Publication number: 20200055883Abstract: Provided herein are compounds useful for the treatment of cancer.Type: ApplicationFiled: February 16, 2018Publication date: February 20, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
-
Patent number: 10537571Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.Type: GrantFiled: June 20, 2017Date of Patent: January 21, 2020Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
-
Publication number: 20190345192Abstract: Provided herein are compounds useful for the treatment of cancer.Type: ApplicationFiled: February 15, 2019Publication date: November 14, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
-
Publication number: 20190337921Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.Type: ApplicationFiled: November 22, 2017Publication date: November 7, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux
-
Patent number: 10246480Abstract: Provided herein are compounds useful for the treatment of cancer.Type: GrantFiled: February 17, 2018Date of Patent: April 2, 2019Assignee: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
-
Publication number: 20180237468Abstract: Provided herein are compounds useful for the treatment of cancer.Type: ApplicationFiled: February 17, 2018Publication date: August 23, 2018Applicant: Eisai R&D Management Co., Ltd.Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
-
Publication number: 20180141913Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.Type: ApplicationFiled: November 22, 2017Publication date: May 24, 2018Applicant: EISAI R & D MANAGEMENT CO., LTD.Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU, Lorna Helen MITCHELL, Nicholas LARSEN, Nathalie RIOUX, Sudeep PRAJAPATI, Dominic REYNOLDS, Morgan O'SHEA, Thiwanka SAMARAKOON
-
Publication number: 20180127378Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.Type: ApplicationFiled: September 22, 2017Publication date: May 10, 2018Applicant: Eisai R&D Management Co., Ltd.Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU
